Danish diabetes and obesity giant Novo Nordisk today announced headline results from STEP UP, a Phase IIIb trial in the ...

The phase 3 STEP UP trial enrolled 1407 adults aged 18 years and older with a body mass index of at least 30kg/m2 and without diabetes.

Ready to crush your New Year’s health goals? These breakthrough medications offer more than weight loss—they support your ...

Injectable GLP-1 agonists help people struggling to lose weight. Patients are finding the drug also helps reduce recurring ...

Wegovy, the weight-loss brand of semaglutide, has a recommended maintenance dose of 2.4 mg. Novo ran the Phase III STEP UP ...

The best semaglutide dose for weight loss varies according to your starting weight, risks, and stage of treatment. Read to ...

Wegovy (semaglutide) is a prescription drug used for weight management and heart disease related to obesity. Wegovy can cause side effects that range from mild to serious. Examples include ...

The New Year is a time of reflection and change for many Americans, who start each January with a clean slate and goals for ...

supporting long-term weight management and improved mental health. 6. Potential kidney protection GLP-1 receptor agonists like semaglutide have demonstrated benefits in slowing the progression of ...